BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline Fierce Biotech Nawigacja wpisu Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab – Nature.com Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb – STAT